{"id":69786,"date":"2024-10-23T07:00:00","date_gmt":"2024-10-23T05:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/"},"modified":"2024-10-28T14:15:10","modified_gmt":"2024-10-28T12:15:10","slug":"ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/","title":{"rendered":"Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l&rsquo;ann\u00e9e 2024 et revoit \u00e0 la hausse ses pr\u00e9visions pour l&rsquo;exercice en cours"},"content":{"rendered":"<p><strong>PARIS, FRANCE, 23 octobre 2024 &#8211; <\/strong>Ipsen (Euronext : IPN ; ADR : IPSEY), groupe biopharmaceutique mondial de sp\u00e9cialit\u00e9, pr\u00e9sente aujourd\u2019hui son chiffre d\u2019affaires r\u00e9alis\u00e9 depuis le d\u00e9but de l\u2019exercice et pour le troisi\u00e8me trimestre 2024.<\/p>\n<table style=\"border-collapse: collapse;margin-left:0.05pt;width:96.9%;border-collapse:collapse\">\n<tr>\n<td rowspan=\"2\" style=\"width:13.42%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     \u00a0<\/p>\n<p>          \u00a0     <\/td>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>9 mois 2024<\/strong>     <\/td>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>9 mois 2023<\/strong>     <\/td>\n<td colspan=\"2\" style=\"width:9.26%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>% Variation<\/strong>     <\/td>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>T3 <\/strong><br \/><strong>2024<\/strong>     <\/td>\n<td style=\"width:4.05%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>T3 <\/strong><br \/><strong>2023<\/strong>     <\/td>\n<td colspan=\"2\" style=\"width:8.93%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>% Variation<\/strong>     <\/td>\n<\/tr>\n<tr>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>\u20acm<\/strong>     <\/td>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>\u20acm<\/strong>     <\/td>\n<td style=\"width:4.69%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>R\u00e9alis\u00e9<\/strong>     <\/td>\n<td style=\"width:4.57%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>TTC<sup>1<\/sup><\/strong>     <\/td>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>m\u20ac<\/strong>     <\/td>\n<td style=\"width:4.05%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>m\u20ac<\/strong>     <\/td>\n<td style=\"width:4.62%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>R\u00e9alis\u00e9<\/strong>     <\/td>\n<td style=\"width:4.31%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>TTC<sup>1<\/sup><\/strong>     <\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.42%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     Oncologie     <\/td>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     1\u00a0829,8     <\/td>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     1 744,1     <\/td>\n<td style=\"width:4.69%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     4,9%     <\/td>\n<td style=\"width:4.57%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     5,8%     <\/td>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     604,0     <\/td>\n<td style=\"width:4.05%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     574,5     <\/td>\n<td style=\"width:4.62%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     5,1%     <\/td>\n<td style=\"width:4.31%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     5,6%     <\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.42%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     Neurosciences     <\/td>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     536,4     <\/td>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     489,0     <\/td>\n<td style=\"width:4.69%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     9,7%     <\/td>\n<td style=\"width:4.57%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     11,8%     <\/td>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     181,9     <\/td>\n<td style=\"width:4.05%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     164,8     <\/td>\n<td style=\"width:4.62%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     10,4%     <\/td>\n<td style=\"width:4.31%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     10,1%     <\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.42%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     Maladies Rares     <\/td>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     129,7     <\/td>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     76,0     <\/td>\n<td style=\"width:4.69%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     70,7%     <\/td>\n<td style=\"width:4.57%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     71,3%     <\/td>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     50,8     <\/td>\n<td style=\"width:4.05%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     33,2     <\/td>\n<td style=\"width:4.62%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     53,1%     <\/td>\n<td style=\"width:4.31%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     54,4%     <\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.42%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>Chiffre d\u2019affaires<\/strong>     <\/td>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>2 495,9<\/strong>     <\/td>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>2 309,1<\/strong>     <\/td>\n<td style=\"width:4.69%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>8,1%<\/strong>     <\/td>\n<td style=\"width:4.57%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>9,2%<\/strong>     <\/td>\n<td style=\"width:4.78%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>836,6<\/strong>     <\/td>\n<td style=\"width:4.05%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>772,4<\/strong>     <\/td>\n<td style=\"width:4.62%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>8,3%<\/strong>     <\/td>\n<td style=\"width:4.31%;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">     <strong>8,6%<\/strong>     <\/td>\n<\/tr>\n<\/table>\n<p><strong>Faits marquants<\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt;text-align:justify\">Croissance du chiffre d\u2019affaires de 9,2% \u00e0 taux de change constant<sup><strong><em>1<\/em><\/strong><\/sup> (8,1% en donn\u00e9es publi\u00e9es) avec des performances significatives de Dysport\u00ae (abobotulinumtoxinA), Cabometyx\u00ae (cabozantinib) et Bylvay\u00ae (odevixibat), des ventes solides de Somatuline\u00ae (lanr\u00e9otide), ainsi qu&rsquo;une contribution croissante des lancements d&rsquo;Iqirvo\u00ae (elafibranor) dans la cholangite biliaire primaire en seconde ligne (CBP) et d&rsquo;Onivyde\u00ae (irinot\u00e9can) dans le traitement de premi\u00e8re ligne de l&rsquo;ad\u00e9nocarcinome canalaire pancr\u00e9atique m\u00e9tastatique.<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Approbation r\u00e9glementaire d&rsquo;Iqirvo et de Kayfanda\u00ae (odevixibat) dans l&rsquo;Union europ\u00e9enne.\u00a0\u00a0<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">R\u00e9vision \u00e0 la hausse des objectifs financiers 2024\u00a0: croissance du chiffre d\u2019affaires sup\u00e9rieure \u00e0 8,0% \u00e0 taux de change constant<sup><strong><em>1<\/em><\/strong><\/sup> (objectif pr\u00e9c\u00e9dent\u00a0: sup\u00e9rieure \u00e0 7,0% \u00e0 taux de change constant<sup><strong><em>1<\/em><\/strong><\/sup>)\u00a0; marge op\u00e9rationnelle des activit\u00e9s sup\u00e9rieure \u00e0 31,0% (objectif pr\u00e9c\u00e9dent\u00a0: sup\u00e9rieure \u00e0 30,0%)<\/li>\n<\/ul>\n<p align=\"justify\">\u00ab\u00a0Depuis le lancement de notre strat\u00e9gie en 2020, nous avons connu une croissance ininterrompue. Ce trimestre n&rsquo;a pas fait exception et s&rsquo;est accompagn\u00e9 de nouveaux progr\u00e8s dans notre portefeuille de m\u00e9dicaments \u00bb, a comment\u00e9 David Loew, directeur g\u00e9n\u00e9ral. \u00ab Nous avons \u00e9galement poursuivi nos lancements dans plusieurs nouvelles indications et lignes th\u00e9rapeutiques pour Iqirvo et d&rsquo;Onivyde, qui se poursuivent \u00e0 un bon rythme. Soutenus par les r\u00e9sultats r\u00e9alis\u00e9s depuis le d\u00e9but de l&rsquo;ann\u00e9e, nous revoyons de nouveau \u00e0 la hausse nos pr\u00e9visions de chiffre d&rsquo;affaires et de marge pour 2024. \u00bb<br \/>\u00ab Nous avons b\u00e2ti au cours des ann\u00e9es un solide historique de r\u00e9sultats, reposant sur la qualit\u00e9 de notre plate-forme d&rsquo;innovation externe, l&rsquo;excellence de notre ex\u00e9cution commerciale et sur notre mission d\u2019offrir plus de choix aux patients. \u00bb<\/p>\n<p align=\"justify\"><strong>Objectifs financiers pour l\u2019ann\u00e9e 2024<\/strong><\/p>\n<p>Sur la base des bonnes performances du troisi\u00e8me trimestre Ipsen revoit de nouveau \u00e0 la hausse ses objectifs financiers pour l\u2019exercice 2024\u00a0:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt;text-align:justify\">Croissance du chiffre d\u2019affaires sup\u00e9rieure \u00e0 8,0%, \u00e0 taux de change constant\u00a0(objectif pr\u00e9c\u00e9dent\u00a0: sup\u00e9rieure \u00e0 7,0% \u00e0 taux de change constant). Sur la base des taux de change moyen en septembre 2024, Ipsen anticipe un impact additionnel d\u00e9favorable des devises de l\u2019ordre de 1,5%.<\/li>\n<li style=\"margin-top:6pt;text-align:justify\">Marge op\u00e9rationnelle des activit\u00e9s sup\u00e9rieure \u00e0 31,0% du chiffre d\u2019affaires, (objectif pr\u00e9c\u00e9dent : sup\u00e9rieur \u00e0 30,0%).<\/li>\n<\/ul>\n<p align=\"justify\"><strong>D\u00e9veloppement du portefeuille de produits en R&amp;D <\/strong><\/p>\n<p align=\"justify\">En septembre 2024, la Commission europ\u00e9enne a approuv\u00e9 sous conditions Iqirvo\u00ae (elafibranor) en comprim\u00e9s de 80 mg pour le traitement de la CBP en association avec l&rsquo;acide ursod\u00e9soxycholique (UDCA) chez les adultes ayant une r\u00e9ponse inad\u00e9quate \u00e0 l&rsquo;UDCA, ou en monoth\u00e9rapie chez les patients ne pouvant tol\u00e9rer l&rsquo;UDCA. Iqirvo a \u00e9t\u00e9 approuv\u00e9 dans le m\u00eame cadre par la FDA am\u00e9ricaine en juin 2024. <\/p>\n<p align=\"justify\">En septembre 2024, la Commission europ\u00e9enne a \u00e9galement approuv\u00e9 Kayfanda\u00ae (odevixibat) comme traitement du prurit chez les enfants \u00e2g\u00e9s de six mois ou plus atteints du syndrome d&rsquo;Alagille (ALGS). L&rsquo;odevixibat, sous la marque Bylvay\u00ae, est d\u00e9j\u00e0 commercialis\u00e9 dans l&rsquo;Union europ\u00e9enne pour le traitement de la cholestase intrah\u00e9patique familiale progressive (CIFP) et aux \u00c9tats-Unis ainsi qu&rsquo;aux \u00c9tats-Unis pour le syndrome d&rsquo;Alagille. <\/p>\n<p align=\"justify\">Ce m\u00eame mois, les r\u00e9sultats finaux de l&rsquo;\u00e9tude de phase III CABINET ont \u00e9t\u00e9 pr\u00e9sent\u00e9s au congr\u00e8s 2024 de la Soci\u00e9t\u00e9 europ\u00e9enne d&rsquo;oncologie m\u00e9dicale et ont \u00e9t\u00e9 publi\u00e9s dans le New England Journal of Medicine, confirmant les b\u00e9n\u00e9fices de l&rsquo;efficacit\u00e9 de Cabometyx\u00ae dans les tumeurs neuroendocrines avanc\u00e9es. Il a \u00e9t\u00e9 annonc\u00e9 \u00e0 cette occasion qu&rsquo;Ipsen avait soumis \u00e0 l&rsquo;Agence europ\u00e9enne des m\u00e9dicaments une demande d&rsquo;extension d&rsquo;indication de l&rsquo;autorisation de mise sur le march\u00e9.<\/p>\n<p align=\"justify\"><strong>Business development <\/strong><\/p>\n<p align=\"justify\">En ao\u00fbt 2024, Ipsen a conclu un accord pour vendre son \u00ab Priority Review Voucher \u00bb pour les maladies p\u00e9diatriques rares. Dans le cadre de cet accord, Ipsen a re\u00e7u un paiement en num\u00e9raire de 158 millions de dollars au troisi\u00e8me trimestre.<br \/>En octobre 2024, Eton Pharmaceuticals a conclu un accord avec Ipsen pour acqu\u00e9rir Increlex\u00ae (mecasermin injectable). La transaction devrait \u00eatre finalis\u00e9e avant la fin de l&rsquo;ann\u00e9e 2024.<\/p>\n<p align=\"justify\"><strong>Proc\u00e9dure d&rsquo;arbitrage avec Galderma<\/strong><\/p>\n<p align=\"justify\">Au 30 septembre 2024, deux proc\u00e9dures d&rsquo;arbitrage initi\u00e9es par Galderma \u00e0 l&rsquo;encontre d&rsquo;Ipsen aupr\u00e8s de la Chambre de Commerce Internationale (CCI) sont en cours. Le premier litige, initi\u00e9 par Galderma en 2021, porte sur la port\u00e9e territoriale du partenariat commercial relatif \u00e0 Azzalure\u00ae (abobotulinumtoxinA) et Dysport dans le cadre d&rsquo;un accord sign\u00e9 en 2007 dans l&rsquo;U.E., dans certains pays d&rsquo;Europe de l&rsquo;Est et en Asie centrale. Le Tribunal de la Cour d&rsquo;arbitrage interne de la CCI a rendu une d\u00e9cision finale, en octobre 2024, rejetant la plupart, sinon toutes, des demandes de Galderma dans ce premier arbitrage et a ordonn\u00e9 que Galderma supporte la majorit\u00e9 des honoraires d&rsquo;avocats et des frais d&rsquo;arbitrage encourus par Ipsen. <br \/>Un second litige a \u00e9t\u00e9 initi\u00e9 par Galderma en novembre 2023, relatif \u00e0 la validit\u00e9 de la r\u00e9siliation par Ipsen en 2023 d&rsquo;un accord de collaboration en R&amp;D conclu en 2014 dans le cadre des programmes de neurotoxines pr\u00e9coces respectifs des parties, y compris le d\u00e9veloppement de l&rsquo;IPN 10200. A ce stade, Ipsen ne peut raisonnablement pr\u00e9dire l&rsquo;impact financier potentiel de cette derni\u00e8re proc\u00e9dure d&rsquo;arbitrage restante, pour laquelle il entend pleinement d\u00e9fendre et faire valoir ses droits.<\/p>\n<p align=\"justify\"><strong>Conf\u00e9rence t\u00e9l\u00e9phonique<\/strong><\/p>\n<p align=\"justify\">Une conf\u00e9rence t\u00e9l\u00e9phonique et un webcast pour les investisseurs et les analystes se tiendront aujourd&rsquo;hui \u00e0 14 heures, heure de Paris. Les participants peuvent acc\u00e9der \u00e0 la conf\u00e9rence t\u00e9l\u00e9phonique en s&rsquo;inscrivant <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4aeLD7AF30I8DoFdOL6zOaG7HoLzBbXfyvFsRW_U1OpADG5xOJ_5whTnzA82GQy_SaZkXWRdNEp19XzimB4rbxMmsTwOGNwlFmWsT_tv4a_d95FAvMvM37vStCfdGLzSWpiIm6EVHP0-XgBczZRYWQ==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"ici\">ici<\/a> ; les d\u00e9tails du webcast sont disponibles <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4aeLD7AF30I8DoFdOL6zOcj2nQqZoqo6EpxdGmy1qsZAl5RFfb8ILek7Gr_7vlOKm09ncikEfjHT66ROFMEG6YRJTfXN2FLk_d-GqBvjB8c=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"ici\">ici<\/a>.<\/p>\n<p align=\"justify\"><strong>Calendrier<\/strong><\/p>\n<p align=\"justify\">Ipsen pr\u00e9voit de publier ses r\u00e9sultats annuels et du quatri\u00e8me trimestre le 13 f\u00e9vrier 2025.<\/p>\n<p align=\"justify\"><strong>Notes<\/strong><\/p>\n<p align=\"justify\">Tous les chiffres financiers sont exprim\u00e9s en millions d\u2019euros. Sauf indication contraire, les performances publi\u00e9es dans le pr\u00e9sent communiqu\u00e9 couvrent la p\u00e9riode de neuf mois courant jusqu\u2019au 30 septembre 2024 (depuis le d\u00e9but de l\u2019exercice, les neuf premiers mois de 2024) et la p\u00e9riode de trois mois jusqu\u2019au 30 septembre 2024 (le troisi\u00e8me trimestre ou T3 2024), comparativement \u00e0 la p\u00e9riode de neuf mois jusqu\u2019au 30 septembre 2023 (les neuf premiers mois de 2023) et la p\u00e9riode de trois mois jusqu\u2019au 30 septembre 2023 (T3 2023) respectivement. Sauf indication contraire, les commentaires sont bas\u00e9s sur les performances r\u00e9alis\u00e9es depuis le d\u00e9but de l\u2019exercice, soit les neuf premiers mois de 2024.<\/p>\n<p><strong>A propos d\u2019Ipsen<\/strong><\/p>\n<p align=\"justify\">Nous sommes un groupe biopharmaceutique mondial focalis\u00e9 sur la mise au point de m\u00e9dicaments innovants pour les patients dans trois domaines th\u00e9rapeutiques : l&rsquo;Oncologie, les Maladies Rares et les Neurosciences. Notre portefeuille de produits en R&amp;D s&rsquo;appuie sur l&rsquo;innovation externe et sur pr\u00e8s de 100 ans d&rsquo;exp\u00e9rience de d\u00e9veloppement au sein de hubs mondiaux aux \u00c9tats-Unis, en France et au Royaume-\u00a0Uni. Nos \u00e9quipes, pr\u00e9sentes dans plus de 40 pays, et nos partenariats \u00e0 travers le monde nous permettent de proposer nos m\u00e9dicaments aux patients dans plus de 100 pays. Ipsen est cot\u00e9 \u00e0 Paris (Euronext : IPN) et aux Etats-Unis \u00e0 travers un programme d\u2019American Depositary Receipt (ADR : IPSEY) sponsoris\u00e9 de niveau I. Pour plus d&rsquo;informations, consultez ipsen.com.<\/p>\n<p><strong>Contacts Ipsen <\/strong><\/p>\n<p><strong>Investisseurs<\/strong><\/p>\n<ul>\n<li style=\"margin-bottom:6pt;text-align:justify\">Craig Marks\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0+44 (0)7584 349 193 <\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">Nicolas Bogler\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0+33 6 52 19 98 92<\/li>\n<\/ul>\n<p>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0<br \/><strong>M\u00e9dias<\/strong><\/p>\n<ul>\n<li style=\"margin-bottom:6pt;text-align:justify\">Jennifer Smith-Parker\u00a0 \u00a0 \u00a0+44 (0) 7843 137 764<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">Anne Liontas\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0+33 7 67 34 72 96<\/li>\n<\/ul>\n<hr \/>\n<p>1 Variation \u00e0 taux de change constant, hors effets de change, \u00e9tabli en recalculant les performances de la p\u00e9riode consid\u00e9r\u00e9e sur la\u00a0base des taux de change utilis\u00e9s pour la p\u00e9riode pr\u00e9c\u00e9dente.<\/p>\n<p id=\"gnw_attachments_section-header\">\n    <strong>Pi\u00e8ce jointe<\/strong>\n<\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=_RlFO8_CQM9zAZCVT7_VYdTkrlzAIp2HvM-3cKdWjQvlhGu0yet6zCEWk66FbfXTK07W-P-1Rrr47Psc5pVtlzn3XsETQqpNgkFlCYWBQF-hK49GQlpy9oPkguKmh6nJ_wTKS5CLXtPomghxYYJSjmhQOLmZuvtM1OcZ62HorkuqKYS17DiMcjvvI7I3Mm-RSKjLSRJyugriQ1vekbRFCA==\" title=\"Ventes au cours des neuf premiers mois de 2024\" rel=\"nofollow noopener\">Ventes au cours des neuf premiers mois de 2024<\/a>\n      <\/li>\n<\/ul>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/Yzg2NzhjZTEtZDVmYy00M2YxLThjODctNzg5ZjQxZWYzN2Q0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[3556,3557],"tags":[],"class_list":["post-69786","press_release","type-press_release","status-publish","hentry","category-corporate-pressrelease-fr","category-financial-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l&#039;ann\u00e9e 2024 et revoit \u00e0 la hausse ses pr\u00e9visions pour l&#039;exercice en cours<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l&#039;ann\u00e9e 2024 et revoit \u00e0 la hausse ses pr\u00e9visions pour l&#039;exercice en cours\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-28T12:15:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/Yzg2NzhjZTEtZDVmYy00M2YxLThjODctNzg5ZjQxZWYzN2Q0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\"},\"headline\":\"Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l&rsquo;ann\u00e9e 2024 et revoit \u00e0 la hausse ses pr\u00e9visions pour l&rsquo;exercice en cours\",\"datePublished\":\"2024-10-23T05:00:00+00:00\",\"dateModified\":\"2024-10-28T12:15:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/\"},\"wordCount\":1364,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/Yzg2NzhjZTEtZDVmYy00M2YxLThjODctNzg5ZjQxZWYzN2Q0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\",\"articleSection\":[\"Corporate\",\"Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/\",\"name\":\"Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l'ann\u00e9e 2024 et revoit \u00e0 la hausse ses pr\u00e9visions pour l'exercice en cours\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/Yzg2NzhjZTEtZDVmYy00M2YxLThjODctNzg5ZjQxZWYzN2Q0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\",\"datePublished\":\"2024-10-23T05:00:00+00:00\",\"dateModified\":\"2024-10-28T12:15:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/Yzg2NzhjZTEtZDVmYy00M2YxLThjODctNzg5ZjQxZWYzN2Q0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/Yzg2NzhjZTEtZDVmYy00M2YxLThjODctNzg5ZjQxZWYzN2Q0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l&#8217;ann\u00e9e 2024 et revoit \u00e0 la hausse ses pr\u00e9visions pour l&#8217;exercice en cours\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l'ann\u00e9e 2024 et revoit \u00e0 la hausse ses pr\u00e9visions pour l'exercice en cours","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l'ann\u00e9e 2024 et revoit \u00e0 la hausse ses pr\u00e9visions pour l'exercice en cours","og_url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/","og_site_name":"Global","article_modified_time":"2024-10-28T12:15:10+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/Yzg2NzhjZTEtZDVmYy00M2YxLThjODctNzg5ZjQxZWYzN2Q0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0"},"headline":"Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l&rsquo;ann\u00e9e 2024 et revoit \u00e0 la hausse ses pr\u00e9visions pour l&rsquo;exercice en cours","datePublished":"2024-10-23T05:00:00+00:00","dateModified":"2024-10-28T12:15:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/"},"wordCount":1364,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/Yzg2NzhjZTEtZDVmYy00M2YxLThjODctNzg5ZjQxZWYzN2Q0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png","articleSection":["Corporate","Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/","url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/","name":"Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l'ann\u00e9e 2024 et revoit \u00e0 la hausse ses pr\u00e9visions pour l'exercice en cours","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/Yzg2NzhjZTEtZDVmYy00M2YxLThjODctNzg5ZjQxZWYzN2Q0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png","datePublished":"2024-10-23T05:00:00+00:00","dateModified":"2024-10-28T12:15:10+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/Yzg2NzhjZTEtZDVmYy00M2YxLThjODctNzg5ZjQxZWYzN2Q0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/Yzg2NzhjZTEtZDVmYy00M2YxLThjODctNzg5ZjQxZWYzN2Q0LTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-enregistre-une-forte-dynamique-commerciale-au-cours-des-neuf-premiers-mois-de-lannee-2024-et-revoit-a-la-hausse-ses-previsions-pour-lexercice-en-cours-2967449\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l&#8217;ann\u00e9e 2024 et revoit \u00e0 la hausse ses pr\u00e9visions pour l&#8217;exercice en cours"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/69786","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":1,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/69786\/revisions"}],"predecessor-version":[{"id":69788,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/69786\/revisions\/69788"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=69786"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=69786"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=69786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}